PROGRAM

Download detailed program: Program2008.pdf (116kb)

Topics

Speakers


Sponsors:

Micromet is a biopharmaceutical company focused on the development and design of novel antibody derived drugs. The Company has built a well-staged pipeline of highly differentiated products for the treatment of cancer, inflammation and autoimmune diseases. All candidates were generated as part of the Company´s own R&D programs. Micromet´s strong pipeline generating and developmental capabilities have enabled the Company to pursue a growth-oriented business strategy and to generate significant revenues through partnerships with companies like Serono and MedImmune Inc. In parallel, Micromet has consolidated key intellectual property in the antibody sector, secured a strong IP position on its candidates and technologies and established an active out-licensing business.


TRION Pharma develops a new class of trifunctional antibodies (triomab®) for highly effective cancer treatments. A state-of-the-art production plant allows cost-effective large-scale manufacture according to international GMP standards. The efficacy of triomab® antibodies in terms of tumour elimination and induction of a polyclonal humoral and cellular anti-tumour immunity has been proven in animal models and in in vivo applications. Catumaxomab and ertumaxomab are currently being developed in a clinical programme featuring several clinical trials together with our cooperation partner Fresenius Biotech. Market entry for the first antibody is expected in 2007.